MY8700655A - 9-shiomaytansinoids their production and use - Google Patents

9-shiomaytansinoids their production and use

Info

Publication number
MY8700655A
MY8700655A MY655/87A MY8700655A MY8700655A MY 8700655 A MY8700655 A MY 8700655A MY 655/87 A MY655/87 A MY 655/87A MY 8700655 A MY8700655 A MY 8700655A MY 8700655 A MY8700655 A MY 8700655A
Authority
MY
Malaysia
Prior art keywords
hydrogen
shiomaytansinoids
production
compounds
thiomaytansinoid
Prior art date
Application number
MY655/87A
Other languages
English (en)
Inventor
Hashimoto Naoto
Shimadzu Hiroshi
Thiomaytansi
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of MY8700655A publication Critical patent/MY8700655A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MY655/87A 1981-05-20 1987-12-30 9-shiomaytansinoids their production and use MY8700655A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56076993A JPS57192389A (en) 1981-05-20 1981-05-20 Novel maytansinoid

Publications (1)

Publication Number Publication Date
MY8700655A true MY8700655A (en) 1987-12-31

Family

ID=13621296

Family Applications (1)

Application Number Title Priority Date Filing Date
MY655/87A MY8700655A (en) 1981-05-20 1987-12-30 9-shiomaytansinoids their production and use

Country Status (7)

Country Link
US (1) US4424219A (Direct)
EP (1) EP0065730B1 (Direct)
JP (1) JPS57192389A (Direct)
AT (1) ATE22082T1 (Direct)
CA (1) CA1169423A (Direct)
DE (1) DE3273121D1 (Direct)
MY (1) MY8700655A (Direct)

Families Citing this family (430)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CN100482281C (zh) 1999-06-25 2009-04-29 基因技术股份有限公司 抗ErbB抗体-类美坦素偶联物在制备药物中的应用
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005049075A2 (en) 2003-11-17 2005-06-02 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
MXPA04006554A (es) 2002-01-02 2005-03-31 Genentech Inc Composiciones y metodos para diagnostico y tratamiento de tumor.
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
WO2004015119A2 (en) * 2002-08-08 2004-02-19 Smithkline Beecham Corporation Methods for the isolation and purification of ansamitocins
US7432088B2 (en) * 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
AU2004239301B2 (en) 2003-05-09 2010-08-19 Diadexus, Inc. OVR110 antibody compositions and methods of use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
DK1651162T3 (en) 2003-05-20 2016-02-01 Immunogen Inc IMPROVED CYTOTOXIC AGENTS WITH NEW MAYTANSINOIDS
DK2784084T4 (da) 2003-07-08 2024-01-08 Novartis Pharma Ag Antagonist-antistoffer mod IL-17A/F heterologe polypeptider
JP2007501011A (ja) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド 制限多様性配列を有する結合型ポリペプチド
ES2384569T3 (es) 2003-12-19 2012-07-09 Genentech, Inc. Fragmentos de anticuerpos monovalentes útiles como agentes terapéuticos
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
KR101254815B1 (ko) 2004-07-20 2013-09-03 제넨테크, 인크. 안지오포이에틴-유사 4 단백질의 저해제, 배합물, 그의용도
BRPI0512482A (pt) 2004-07-26 2008-03-11 Genentech Inc método de identificação de uma substáncia inibidora candidata e molécula antagonista
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
MX337423B (es) * 2004-09-03 2016-03-04 Genentech Inc Antagonistas anti-beta7 humanizados y usos para los mismos.
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
DE602006013275D1 (de) 2005-01-07 2010-05-12 Diadexus Inc Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
WO2006086733A2 (en) 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
JP2008541781A (ja) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
WO2007094842A2 (en) * 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
EP1922410A2 (en) 2005-08-15 2008-05-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EA013327B1 (ru) * 2005-08-24 2010-04-30 Иммуноджен, Инк. Способ приготовления очищенных конъюгатов лекарственных средств
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP3006466B1 (en) 2005-12-02 2018-08-01 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
WO2007120334A2 (en) 2005-12-15 2007-10-25 Genentech, Inc. Methods and compositions for targeting polyubiquitin
RU2450020C2 (ru) 2006-01-05 2012-05-10 Дженентек, Инк. АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR101617108B1 (ko) 2006-01-20 2016-04-29 제넨테크, 인크. 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법
EP1988768A2 (en) 2006-02-17 2008-11-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
EP2007428A2 (en) 2006-04-05 2008-12-31 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
PL2032606T3 (pl) 2006-05-30 2014-04-30 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowania
BRPI0714871A2 (pt) 2006-07-18 2013-05-07 Sanofi-Aventis anticorpo antagonista para o tratamento de cÂncer
ES2372217T3 (es) 2006-09-12 2012-01-17 Genentech, Inc. Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2667019C (en) 2006-10-27 2016-03-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2008066752A2 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R & D Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
AU2008216495A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
TWI417099B (zh) 2007-03-23 2013-12-01 Neuraxon Inc 具抑制一氧化氮合成酶活性之喹諾酮、四氫喹啉及其相關化合物
KR101540822B1 (ko) 2007-03-27 2015-07-30 씨 레인 바이오테크놀로지스, 엘엘씨 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CA3160831A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
CN101802013B (zh) 2007-07-16 2014-07-02 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
CN104017079B (zh) 2007-08-29 2017-01-04 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2008321016B2 (en) 2007-11-12 2013-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US9011864B2 (en) * 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
HRP20140604T1 (hr) 2007-12-26 2014-09-12 Biotest Ag Sredstva koja djeluju na cd138 i njihova upotreba
RU2486203C2 (ru) * 2007-12-26 2013-06-27 Биотест Аг Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления
AU2008339911B2 (en) * 2007-12-26 2014-02-27 Biotest Ag Immunoconjugates targeting CD138 and uses thereof
EP2247617B1 (en) 2008-01-18 2013-02-27 Genentech, Inc. Methods and compositions for targeting polyubiquitin
EP3269737B1 (en) 2008-01-31 2024-06-19 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
EP2257571B1 (en) 2008-03-10 2015-03-04 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
NZ621433A (en) 2008-03-18 2015-10-30 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
CA2905334A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
KR20210005318A (ko) 2008-04-30 2021-01-13 이뮤노젠 아이엔씨 가교제 및 그 용도
BRPI0908665A2 (pt) * 2008-05-16 2020-08-18 Genentech Inc método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
NZ591488A (en) 2008-09-07 2012-11-30 Glyconex Inc Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
WO2010039832A1 (en) 2008-10-01 2010-04-08 Genentech, Inc. Anti-notch2 antibodies and methods of use
WO2010080528A1 (en) 2008-12-17 2010-07-15 Genentech, Inc. Hepatitis c virus combination therapy
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US8410250B2 (en) * 2009-03-25 2013-04-02 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
SG175004A1 (en) 2009-04-02 2011-11-28 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
WO2010126979A1 (en) 2009-04-29 2010-11-04 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP3480202A1 (en) 2009-06-03 2019-05-08 ImmunoGen, Inc. Conjugation methods
CN106117348A (zh) 2009-06-04 2016-11-16 诺华公司 识别IgG结合位点的方法
CN102802661B (zh) 2009-06-22 2016-01-13 米迪缪尼有限公司 用于位点特异性偶联的工程改造的Fc区
CA2769308A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5887270B2 (ja) 2009-09-02 2016-03-16 ジェネンテック， インコーポレイテッド 突然変異体ｓｍｏｏｔｈｅｎｅｄおよびその使用方法
NZ701769A (en) 2009-09-16 2016-06-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
RU2012120693A (ru) * 2009-10-19 2013-12-20 Дженентек, Инк. Модуляторы активатора фактора роста гепатоцитов
CN102711826B (zh) 2009-10-22 2017-03-29 霍夫曼-拉罗奇有限公司 用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
CN102648211B (zh) 2009-10-22 2015-04-01 霍夫曼-拉罗奇有限公司 抗hepsin抗体及其使用方法
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
ES2636971T3 (es) 2009-11-05 2017-10-10 F. Hoffmann-La Roche Ag Procedimientos y composición para la secreción de polipéptidos heterógenos
RU2015132142A (ru) 2009-11-30 2015-12-20 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
CN107337734A (zh) 2009-12-04 2017-11-10 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
EP2509626B1 (en) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c antibodies and methods using same
ES2585350T3 (es) 2009-12-23 2016-10-05 F. Hoffmann-La Roche Ag Anticuerpos anti Bv8 y usos de los mismos
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
AU2011221226A1 (en) 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
MY171234A (en) 2010-02-24 2019-10-04 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
SI2544719T1 (sl) 2010-03-12 2019-11-29 Debiopharm Int Sa CD37-povezovalne molekule in njihovi imunokonjugati
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
PE20130460A1 (es) 2010-05-03 2013-04-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
NZ602840A (en) 2010-06-03 2014-11-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
CA2807664A1 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
PL3556396T3 (pl) 2010-08-31 2022-09-12 Theraclone Sciences, Inc. Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
ES2588981T3 (es) 2010-10-05 2016-11-08 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
EP2632490A4 (en) 2010-10-29 2014-10-22 Immunogen Inc NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
CA2825064C (en) 2011-02-04 2022-08-30 Genentech, Inc. Fc variants and methods for their production
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
KR20140012098A (ko) 2011-02-14 2014-01-29 테라클론 사이언시스, 아이엔씨. 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
US8753634B2 (en) 2011-03-03 2014-06-17 Apexigen, Inc. Anti-IL-6 receptor antibodies and methods of use
JP2014509591A (ja) 2011-03-15 2014-04-21 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
PL3235508T3 (pl) 2011-03-16 2021-07-12 Sanofi Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
JP6000329B2 (ja) 2011-03-29 2016-09-28 イムノゲン インコーポレーティッド １段階の工程によるマイタンシノイド−抗体複合体の調製
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
CN103648523A (zh) 2011-05-09 2014-03-19 弗吉尼亚大学专利基金会 用于治疗癌症的组合物和方法
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
MX2013014583A (es) 2011-06-10 2014-03-31 Mersana Therapeutics Inc Conjugados de proteina-polimero-farmaco.
AU2012272930B2 (en) 2011-06-21 2015-06-11 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
RU2014109985A (ru) 2011-08-17 2015-09-27 Дженентек, Инк. Ингибирование ангиогенеза в рефрактерных опухолях
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
CA2849318C (en) 2011-09-22 2019-11-12 Amgen Inc. Cd27l antigen binding proteins
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP6310394B2 (ja) 2011-10-10 2018-04-11 ゼンコア インコーポレイテッド 抗体を精製する方法
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EA201490879A1 (ru) 2011-10-28 2014-08-29 Дженентек, Инк. Терапевтические комбинации и способы лечения меланомы
EP2785742B1 (en) 2011-11-02 2020-01-08 Apexigen, Inc. Anti-kdr antibodies and methods of use
CA2856411A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
RU2632108C2 (ru) 2011-12-08 2017-10-02 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CA2862292C (en) 2012-01-20 2019-10-08 Sea Lane Biotechnologies, Llc Binding molecule conjugates
RU2644341C2 (ru) 2012-02-10 2018-02-08 Дженентек, Инк. Одноцепочечные антитела и другие гетеромультимеры
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CN104379602B (zh) 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013256596A1 (en) 2012-05-01 2014-10-09 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
SG11201501286PA (en) 2012-08-23 2015-05-28 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
HK1213288A1 (zh) 2012-10-04 2016-06-30 Immunogen, Inc. 使用pvdf膜純化細胞結合劑細胞毒性劑綴合物
AU2013337903B2 (en) 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
JP6334553B2 (ja) 2012-12-10 2018-05-30 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
ES2871816T3 (es) 2012-12-27 2021-11-02 Sanofi Sa Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US10150813B2 (en) 2013-03-14 2018-12-11 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP2951203B1 (en) 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CN105007950B (zh) 2013-03-15 2019-01-15 诺华股份有限公司 抗体药物缀合物
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
NZ753995A (en) 2013-05-30 2022-07-01 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN111518199A (zh) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
EP3747465A1 (en) 2013-07-31 2020-12-09 BioNTech AG Diagnosis and therapy of cancer involving cancer stem cells
TWI646108B (zh) 2013-08-01 2019-01-01 艾澤西公司 結合至ｃｄ３７蛋白質之抗體藥物結合物（ａｄｃ）
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
EP3041484B1 (en) 2013-09-06 2021-03-03 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
JP6282745B2 (ja) 2013-09-12 2018-02-21 ハロザイム インコーポレイテッド 修飾抗上皮成長因子受容体抗体およびその使用法
BR112016004450A2 (pt) 2013-09-17 2017-10-17 Genentech Inc métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
DK3653228T3 (da) 2013-10-08 2024-07-15 Immunogen Inc Anti-folr1-immunkonjugatdoseringsregimer
CN115068626A (zh) 2013-10-11 2022-09-20 阿萨纳生物科技有限责任公司 蛋白-聚合物-药物缀合物
AU2014333563B9 (en) 2013-10-11 2020-04-02 Oxford Biotherapeutics Ltd Conjugated antibodies against LY75 for the treatment of cancer
US9849191B2 (en) 2013-10-11 2017-12-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
ES2764833T3 (es) 2013-10-11 2020-06-04 The United States Of America Represented By The Sec Dep Of Health And Human Services Anticuerpos contra TEM8 y su uso
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
KR20160083949A (ko) 2013-11-13 2016-07-12 자임워크스 인코포레이티드 Egfr 및/또는 her2를 표적화하는 1가 항원 결합 작제물 및 이의 용도
EA201691214A1 (ru) 2013-12-13 2016-12-30 Дженентек, Инк. Антитела к cd33 и иммуноконъюгаты
KR20170042495A (ko) 2013-12-16 2017-04-19 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017505305A (ja) 2014-01-24 2017-02-16 ジェネンテック， インコーポレイテッド 抗ｓｔｅａｐ１抗体及びイムノコンジュゲートを使用する方法
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
CA2938919C (en) 2014-02-28 2020-12-29 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
KR20230022270A (ko) 2014-03-28 2023-02-14 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
PL3140392T3 (pl) 2014-05-06 2023-11-27 F. Hoffmann-La Roche Ag Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
KR102576850B1 (ko) 2014-05-27 2023-09-11 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
CN106714829A (zh) 2014-05-28 2017-05-24 中央研究院 抗TNF‑α醣抗体及其用途
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9982045B2 (en) 2014-08-12 2018-05-29 Novartis Ag Anti-CDH6 antibody drug conjugates
DK4074735T3 (da) 2014-08-28 2025-07-14 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
JP2017526682A (ja) 2014-09-02 2017-09-14 イミュノジェン， インコーポレイテッド 抗体薬物複合体組成物の製剤化方法
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
KR20170066421A (ko) 2014-09-12 2017-06-14 제넨테크, 인크. 항-cll-1 항체 및 면역접합체
WO2016040723A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-her2 antibodies and immunoconjugates
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
BR112017023576A2 (pt) 2014-09-23 2023-10-03 Genentech Inc Método para tratar uma disfunção proliferativa de células b
ES2969960T3 (es) 2014-10-01 2024-05-23 Medimmune Llc Método para conjugar un polipéptido
MX2017003478A (es) 2014-11-05 2018-02-01 Genentech Inc Anticuerpos anti-fgfr2/3 y metodos para su uso.
MA40934A (fr) 2014-11-19 2017-09-27 Immunogen Inc Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
CU24597B1 (es) 2014-11-26 2022-05-11 Xencor Inc Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
CA2969584C (en) 2014-12-04 2023-03-14 Celgene Corporation Biomolecule conjugates
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI710571B (zh) 2015-01-24 2020-11-21 中央研究院 腫瘤標記及其使用方法
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
CN107636170A (zh) 2015-02-04 2018-01-26 健泰科生物技术公司 突变型Smoothened及其使用方法
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2016145536A1 (en) 2015-03-18 2016-09-22 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
EP3286227A2 (en) 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Multispecific antigen-binding proteins
CA2989347A1 (en) 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
EP4477269A3 (en) 2015-09-20 2025-03-19 The United States of America, as Represented By the Secretary, Department of Health and Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
CN114181960B (zh) 2015-10-09 2024-08-23 美天施生物科技有限公司 嵌合抗原受体和使用方法
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
AU2017212484C1 (en) 2016-01-27 2020-11-05 Medimmune, Llc Methods for preparing antibodies with a defined glycosylation pattern
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
CA3013125A1 (en) 2016-02-05 2017-08-10 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
KR102466763B1 (ko) 2016-04-13 2022-11-11 오리맵스 리미티드 항- psma 항체 및 이의 용도
CN109563164A (zh) 2016-04-15 2019-04-02 生物蛋白有限公司 抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
SMT202200432T1 (it) 2016-05-13 2022-11-18 Bioatla Inc Anticorpi, frammenti anticorpali anti-ror2, loro immunoconiugati e loro usi
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP3474901B1 (en) 2016-06-27 2025-08-06 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
WO2018026533A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11453712B2 (en) 2016-09-02 2022-09-27 Lentigen Technology Inc. Compositions and methods for treating cancer with DuoCARs
KR102562519B1 (ko) 2016-10-14 2023-08-02 젠코어 인코포레이티드 IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
MX2019005583A (es) 2016-11-14 2019-10-21 Hangzhou Dac Biotech Co Ltd Vinculantes de conjugacion, conjugados de molecula de union a celulas que contienen los vinculantes, metodos de creacion y usos de dichos conjugados con los vinculantes.
US11697680B2 (en) 2016-11-21 2023-07-11 Cureab Gmbh Anti-GP73 antibodies and immunoconjugates
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
CA3096798A1 (en) 2017-01-09 2018-07-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
CN112695050B (zh) 2017-03-24 2025-08-08 莱蒂恩技术公司 用于用抗cd33免疫疗法治疗癌症的组合物和方法
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AU2018268970B2 (en) 2017-05-19 2024-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
JP7320458B2 (ja) 2017-06-22 2023-08-03 メルサナ セラピューティクス インコーポレイテッド 薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
EP3645122A1 (en) 2017-06-30 2020-05-06 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
CA3071624A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
CN120571030A (zh) 2017-08-22 2025-09-02 普渡研究基金会 靶向碳酸酐酶阳性癌症的基于fbsa的治疗和放射性成像缀合物
EP3681903B1 (en) 2017-09-15 2023-07-19 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19 immunotherapy
EP3697426B1 (en) 2017-10-16 2023-07-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
AU2018354189A1 (en) 2017-10-24 2020-04-23 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
CN111741757B (zh) 2017-11-03 2023-12-19 莱蒂恩技术公司 用于用抗ror1免疫治疗来治疗癌症的组合物和方法
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
MX2020004910A (es) 2017-11-29 2020-10-05 Magenta Therapeutics Inc Composiciones y métodos para el agotamiento de células cd5 +.
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
CN111954677A (zh) 2017-12-20 2020-11-17 莱蒂恩技术公司 用于用免疫治疗来治疗hiv/aids的组合物和方法
WO2019183438A1 (en) 2018-03-23 2019-09-26 Seattle Genetics, Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
CA3099419A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
DK3788032T3 (da) 2018-05-04 2024-04-15 Tagworks Pharmaceuticals B V Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
BR112020024040A2 (pt) 2018-05-30 2021-04-06 Debiopharm International, S.A. Regimes de dosagem de imunoconjugado anti-cd37
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
SG11202013138RA (en) 2018-07-02 2021-01-28 Amgen Inc Anti-steap1 antigen-binding protein
AU2019301675B2 (en) 2018-07-12 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
AU2019311077B2 (en) 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
CN112585163B (zh) 2018-08-08 2025-03-25 美国政府(由卫生和人类服务部的部长所代表) 靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
CN113260630B (zh) 2018-09-20 2024-05-24 莱蒂恩技术公司 用于用抗cd123免疫治疗来治疗癌症的组合物和方法
CN118581122A (zh) 2018-09-26 2024-09-03 莱蒂恩技术公司 用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
EA202191175A1 (ru) 2018-10-29 2021-09-08 Мерсана Терапьютикс, Инк. Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
CA3121244A1 (en) 2018-11-30 2020-06-04 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd38 immunotherapy
AU2018451747A1 (en) 2018-12-06 2021-06-17 F. Hoffmann-La Roche Ag Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
CA3125484A1 (en) 2019-01-08 2020-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
CN113784987B (zh) 2019-01-22 2024-09-13 美国政府(由卫生和人类服务部的部长所代表) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
AU2020219405A1 (en) 2019-02-07 2021-08-26 Sanofi Use of anti-CEACAM5 immunoconjugates for treating lung cancer
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
EP3934668A1 (en) 2019-03-06 2022-01-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
WO2020232169A1 (en) 2019-05-14 2020-11-19 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
US11052112B2 (en) 2019-05-30 2021-07-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-BCMA immunotherapy
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
AU2020297253B2 (en) 2019-06-17 2024-05-23 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
EP3994173A1 (en) 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
JPWO2021010326A1 (Direct) 2019-07-12 2021-01-21
CN114945386A (zh) 2019-10-18 2022-08-26 基因泰克公司 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
CA3156761A1 (en) 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
WO2021118968A1 (en) 2019-12-12 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for cd276 and uses thereof
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
CA3181000A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
KR20230005203A (ko) 2020-04-24 2023-01-09 사노피 항-ceacam5 항체 접합체 및 folfox를 함유하는 항종양 조합
TW202203981A (zh) 2020-04-24 2022-02-01 法商賽諾菲公司 含有抗ｃｅａｃａｍ５抗體接合物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）的抗腫瘤組合
BR112022020592A2 (pt) 2020-04-24 2022-11-29 Sanofi Sa Combinações antitumor contendo conjugados de anticorpo anti-ceacam5, trifluridina e tipiracila
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3171101A1 (en) 2020-06-22 2021-12-30 Dina SCHNEIDER Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CA3171093A1 (en) 2020-11-05 2022-05-12 Dina SCHNEIDER Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
AU2021376218A1 (en) 2020-11-08 2023-06-15 Seagen Inc. Combination Therapy
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
TW202304524A (zh) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1結合劑、其結合物及使用方法
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
US20240218055A1 (en) 2021-04-29 2024-07-04 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
WO2022241446A1 (en) 2021-05-12 2022-11-17 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN117396513A (zh) 2021-05-28 2024-01-12 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的联合疗法
US20240270851A1 (en) 2021-06-09 2024-08-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US20250327057A1 (en) 2021-09-06 2025-10-23 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
CN118159294A (zh) 2021-10-05 2024-06-07 葛兰素史密斯克莱知识产权发展有限公司 用于治疗癌症的联合疗法
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
EP4426736A1 (en) 2021-11-05 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
WO2023089314A1 (en) 2021-11-18 2023-05-25 Oxford Biotherapeutics Limited Pharmaceutical combinations
CA3238167A1 (en) 2021-11-19 2023-05-25 Maria Leia Smith Gpc3 binding agents, conjugates thereof and methods of using the same
DK4186529T3 (da) 2021-11-25 2025-08-25 Veraxa Biotech Gmbh Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
WO2023094525A1 (en) 2021-11-25 2023-06-01 Veraxa Biotech Gmbh Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
EP4440603A1 (en) 2021-12-02 2024-10-09 Sanofi Cea assay for patient selection in cancer therapy
MX2024006765A (es) 2021-12-02 2024-07-29 Sanofi Sa Terapia de combinación con adc ceacam5 - anti-pd1/pd-l1.
AU2022404647A1 (en) 2021-12-08 2024-06-13 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
JP2024546948A (ja) 2021-12-15 2024-12-26 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド コンジュゲート、それらの組成物、及びそれらの関連する方法
WO2023158305A1 (en) 2022-02-15 2023-08-24 Tagworks Pharmaceuticals B.V. Masked il12 protein
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
CN119923410A (zh) 2022-07-28 2025-05-02 莱蒂恩技术公司 用于治疗实体瘤的嵌合抗原受体治疗
CA3265857A1 (en) 2022-08-26 2024-02-29 Lentigen Technology, Inc. COMPOSITIONS AND METHODS OF CANCER TREATMENT BY ALL-HUMAN ANTI-CD20/CD19 IMMUNOTHERAPY
EP4602023A1 (en) 2022-10-12 2025-08-20 Tagworks Pharmaceuticals B.V. Strained bicyclononenes
CN120569216A (zh) 2023-01-20 2025-08-29 巴斯夫欧洲公司 稳定型生物聚合物组合物、其制造和用途
EP4673181A1 (en) 2023-03-01 2026-01-07 Sanofi Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
EP4427763A1 (en) 2023-03-06 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
AU2024237490A1 (en) 2023-03-10 2025-09-25 Tagworks Pharmaceuticals B.V. Trans-cyclooctene with improved t-linker
EP4684034A1 (en) 2023-03-23 2026-01-28 Sanofi Ceacam5 mrna assay for patient selection in cancer therapy
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
WO2024251733A1 (en) 2023-06-05 2024-12-12 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies
AU2024283865A1 (en) 2023-06-08 2025-11-27 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025021929A1 (en) 2023-07-27 2025-01-30 Veraxa Biotech Gmbh Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
WO2025056807A1 (en) 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025169012A1 (en) 2024-02-06 2025-08-14 Sanofi Methods of treating ceacam5-expressing cancers
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
WO2025174248A1 (en) 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctenes with "or gate" release
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2026006682A1 (en) 2024-06-27 2026-01-02 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating cancer with il7fc armored car-t cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5622790A (en) 1979-07-31 1981-03-03 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation

Also Published As

Publication number Publication date
JPH0114918B2 (Direct) 1989-03-14
EP0065730A1 (en) 1982-12-01
JPS57192389A (en) 1982-11-26
ATE22082T1 (de) 1986-09-15
US4424219A (en) 1984-01-03
CA1169423A (en) 1984-06-19
EP0065730B1 (en) 1986-09-10
DE3273121D1 (en) 1986-10-16

Similar Documents

Publication Publication Date Title
DE3273121D1 (en) 9-thiomaytansinoids, their production and use
CA1238910A (en) CARBOXYALKENOIC ACIDS
NZ237132A (en) Preparation of substituted oxetanones from beta-hydroxy-omega-lactones; various beta-hydroxy and beta-keto-omega-lactones
ZA813903B (en) Preparation of fluoro vinyl ethers
FR2383171A1 (fr) Derives de thiopropanoylaminoacides utiles comme hypotenseurs
ES445928A1 (es) Procedimiento para la preparacion de compuestos de imidazo- linio cuaternarios.
FR2436150A1 (fr) Derives de 3'',4''-diacyltylosine utiles comme medicaments
FR2375239A1 (fr) Derives d'acide 7-amino-8-oxo-3-oxa-1-azabicyclo-(4.2.0)octane-2-carboxylique
GR72471B (Direct)
FR2383931A1 (fr) Derives d'oxadiazolopyrimidine
IE822391L (en) 4-acylamino-1-azaadamantanes
GB1498931A (en) Tetrahalopentyl ketone derivatives processes for producing them and their conversion to beta-dihaloethenylcyclopropane derivatives
FR2359813A1 (fr) Nouveaux esters d'acide cyclobutane carboxylique utile pour lutter contre les parasites
FI932126A0 (fi) Foerfarande foer framstaellning av 2-klor-5-klormetylpyridin
ES8306997A1 (es) Procedimiento para preparar un derivado de prostaglandina.
GB1244910A (en) Preparation of (cis-1,2-epoxypropyl)phosphonic acid, derivatives thereof and intermediates therefor
FR2380271A1 (fr) Acides halogene-benzofuranone-carboxyliques utiles comme intermediaires de synthese
ES2026416A6 (es) Procedimiento para la preparacion de triazolil-isopropanol.
FR2360604A1 (fr) Nouveaux derives d'imidazole utiles comme medicaments
GB1380733A (en) Polyene compounds and processes for the manufacture thereof
GB2002350A (en) Preparation of tetramisole intermediate
FR2416223A1 (fr) Derives de phenylpyrol utilisables comme fongicides
JPS5711938A (en) Preparation of 1,1-dialkoxy-3-alkynes
PH19573A (en) Process and intermediates for preparation of 1,1-dixopenicillanoyloxymethyl 6-beta aminopenicillanate
CS8103958A2 (en) Zpusob vyroby uhlovodikoveho roztoku alkylsodne slouceniny